Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT - Full Text View

Purpose

The purpose of this study is to determine the efficacy and effectiveness of calcium channel blockers and adenosine in the treatment of Supraventricular Tachycardia.

Condition	Intervention	Phase
Supraventricular Tachycardia	Drug: Calcium Channel Blocker & Adenosine	Phase IV

Genetics Home Reference related topics:

Brugada syndrome short QT syndrome

ChemIDplus related topics:

Calcium gluconate Diltiazem Verapamil Dexverapamil Diltiazem hydrochloride Diltiazem malate Verapamil hydrochloride Adenosine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study

Official Title:	Comparism Between Efficacy and Effectiveness Between Slow Infusion of Calcium Channel Blockers and Intravenous Bolus Adenosine in the Management of Supraventricular Tachycardia in the Emergency Department.

Further study details as provided by Singapore General Hospital:

Primary Outcome Measures:

Conversion to the sinus rhythm.

Secondary Outcome Measures:

Recurrence of SVT
Stability of vital signs

Estimated Enrollment:	206
Study Start Date:	January 1997
Estimated Study Completion Date:	March 2001

Show Detailed Description

Eligibility

Ages Eligible for Study:	10 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

More than 10 years old
Electrocardiographic diagnosis of SVT
SVT not converted by the vagal manoeuvres

Exclusion Criteria:

Signs of impaired cerebral perfusion
Signs of pulmonary oedema
Subsequent diagnosis of other types of arrythmias rather than SVT
pregnancy by history

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00413712

Locations


Singapore
	Singapore General Hospital
	Singapore, Singapore, 62223322

Sponsors and Collaborators

Singapore General Hospital

Investigators


Principal Investigator:	Lim S Han, MBBS,FRCS	Department of Emergency Medicine, Singapore General Hospital

More Information

Publications:

Lim SH, Anantharaman V, Teo WS. Slow-infusion of calcium channel blockers in the emergency management of supraventricular tachycardia. Resuscitation. 2002 Feb;52(2):167-74.

Brady WJ Jr, DeBehnke DJ, Wickman LL, Lindbeck G. Treatment of out-of-hospital supraventricular tachycardia: adenosine vs verapamil. Acad Emerg Med. 1996 Jun;3(6):574-85.

Madsen CD, Pointer JE, Lynch TG. A comparison of adenosine and verapamil for the treatment of supraventricular tachycardia in the prehospital setting. Ann Emerg Med. 1995 May;25(5):649-55.

Sethi KK, Singh B, Kalra GS, Arora R, Khalilullah M. Comparative clinical and electrophysiologic effects of adenosine and verapamil on termination of paroxysmal supraventricular tachycardia. Indian Heart J. 1994 May-Jun;46(3):141-4.

Viskin S, Belhassen B. Acute management of paroxysmal atrioventricular junctional reentrant supraventricular tachycardia: pharmacologic strategies. Am Heart J. 1990 Jul;120(1):180-8. Review.

Camm AJ, Garratt CJ. Adenosine and supraventricular tachycardia. N Engl J Med. 1991 Dec 5;325(23):1621-9. Review. No abstract available.

Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1991 Jul;20(7):717-21.

DiMarco JP, Miles W, Akhtar M, Milstein S, Sharma AD, Platia E, McGovern B, Scheinman MM, Govier WC. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med. 1990 Jul 15;113(2):104-10. Erratum in: Ann Intern Med 1990 Dec 15;113(12):996.

Viskin S, Belhassen B. Acute management of paroxysmal atrioventricular junctional reentrant supraventricular tachycardia: pharmacologic strategies. Am Heart J. 1990 Jul;120(1):180-8. Review.

Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis. 1989 Jul-Aug;32(1):73-97. Review. No abstract available.

Garratt C, Linker N, Griffith M, Ward D, Camm AJ. Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia. Am J Cardiol. 1989 Dec 1;64(19):1310-6.

Belhassen B, Glick A, Laniado S. Comparative clinical and electrophysiologic effects of adenosine triphosphate and verapamil on paroxysmal reciprocating junctional tachycardia. Circulation. 1988 Apr;77(4):795-805.

Klein HO, Ninio R, Oren V, Lang R, Sareli P, DiSegni E, David D, Guerrero J, Kaplinsky E. The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment by equilibrium-gated radionuclide ventriculography. Circulation. 1983 Jan;67(1):101-10.

Betriu A, Chaitman BR, Bourassa MG, Brevers G, Scholl JM, Bruneau P, Gagne P, Chabot M. Beneficial effect of intravenous diltiazem in the acute management of paroxysmal supraventricular tachyarrhythmias. Circulation. 1983 Jan;67(1):88-94.

Mitchell LB, Schroeder JS, Mason JW. Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review. Am J Cardiol. 1982 Feb 18;49(3):629-35.

Singh BN, Hecht HS, Nademanee K, Chew CY. Electrophysiologic and hemodynamic effects of slow-channel blocking drugs. Prog Cardiovasc Dis. 1982 Sep-Oct;25(2):103-32. Review. No abstract available.

Kawai C, Konishi T, Matsuyama E, Okazaki H. Comparative effects of three calcium antagonists, diltiazem, verapamil and nifedipine, on the sinoatrial and atrioventricular nodes. Experimental and clinical studies. Circulation. 1981 May;63(5):1035-42.

Henderson AH, Lewis MJ. Basic mechanisms of 'calcium antagonists' (slow channel blockers). Scott Med J. 1981 Apr;26(2):156-60. Review. No abstract available.

Russell DC. Electrophysiology and antiarrhythmic effects of calcium antagonists. Scott Med J. 1981 Apr;26(2):161-4. Review. No abstract available.

Sung RJ, Elser B, McAllister RG Jr. Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med. 1980 Nov;93(5):682-9.

Seipel L, Breithardt G, Abendroth RR, Wiebringhaus E. [The electrophysiological effects of the Ca-antagonists gallopamil (D 600), dimeditiapramine (Ro 11-1781) and verapamil in man (author's transl)] Z Kardiol. 1980 Aug;69(8):551-5. German.

Singh BN, Roche AH. Effects of intravenous verapamil on hemodynamics in patients with heart disease. Am Heart J. 1977 Nov;94(5):593-9.

Heng MK, Singh BN, Roche AH, Norris RM, Mercer CJ. Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. Am Heart J. 1975 Oct;90(4):487-98.

Schamroth L, Krikler DM, Garrett C. Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J. 1972 Mar 11;1(5801):660-2. No abstract available.

Study ID Numbers:	IRB18/1997
First Received:	December 19, 2006
Last Updated:	December 19, 2006
ClinicalTrials.gov Identifier:	NCT00413712
Health Authority:	Singapore: Health Sciences Authority

Keywords provided by Singapore General Hospital:

Supraventricular Tachycardia

Calcium Channel Blockers

Verapamil

Diltiazem

Adenosine

Study placed in the following topic categories:

Tachycardia, Supraventricular

Verapamil

Heart Diseases

Tachycardia

Diltiazem

Emergencies

Adenosine

Arrhythmias, Cardiac

Additional relevant MeSH terms:

Disease Attributes

Vasodilator Agents

Physiological Effects of Drugs

Cardiovascular Agents

Pharmacologic Actions

Pathologic Processes

Sensory System Agents

Therapeutic Uses

Cardiovascular Diseases

Analgesics

Peripheral Nervous System Agents

Anti-Arrhythmia Agents

Central Nervous System Agents

ClinicalTrials.gov processed this record on September 05, 2008

Sponsored by:	Singapore General Hospital
Information provided by:	Singapore General Hospital
ClinicalTrials.gov Identifier:	NCT00413712